Application of a composition containing riluzole and borneol in preparing a drug for treating cerebrovascular disease
Through the composition of 2-amino-6-trifluoromethoxybenzothiazole and dextaneol, the limited efficacy of existing drugs in the treatment of ischemic cerebrovascular disease and cerebral infarction is solved, through non-clinical and Animal tests have verified its significant neuroprotection and reduction of cerebral infarction, achieving stronger efficacy.
Patent Information
- Application Number
- CN202110141522.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-02-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-02-02
AI Technical Summary
Existing drugs for treating cerebrovascular diseases are difficult to effectively target ischemic cerebrovascular diseases, especially ischemic stroke, and the efficacy of a single drug is limited.
Using a composition of 2-amino-6-trifluoromethoxybenzothiazole (riluzole) and dextranol, the mass ratio of the drug is optimized to enhance the drug effect through non-clinical cell tests and animal drug efficacy tests. In the preparation of drugs for cerebrovascular diseases.
Compositions of 2-amino-6-trifluoromethoxybenzothiazole and dextranol significantly increased the effect on the inhibition rate of NMDA-induced neuronal damage and reduced cerebral infarction area in non-clinical cell tests and animal models , demonstrates the effect of synergistically increasing the efficacy of the drug, which is better than the protective effect of a single drug.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the pharmaceutical field and relates to the application of a composition of 2-amino-6-trifluoromethoxybenzothiazole and borneol or dextrorotatory borneol in the preparation of a drug for treating cerebrovascular disease, in particular ischemic cerebrovascular disease. Background Art
[0002] Cerebrovascular disease (CVD) refers to brain lesions caused by various cerebrovascular diseases. According to the course of the disease, it can be divided into acute cerebrovascular disease (stroke) and chronic cerebrovascular disease. Acute cerebrovascular disease includes transient ischemic attack, cerebral thrombosis, cerebral embolism, hypertensive encephalopathy, cerebral hemorrhage and subarachnoid hemorrhage; chronic cerebrovascular disease includes cerebral arteriosclerosis, cerebrovascular dementia, cerebral artery steal syndrome, Parkinson's disease, etc. Ischemic stroke refers to the general term for brain tissue necrosis caused by stenosis or occlusion of the blood supply arteries (carotid artery and vertebral artery) of the brain and insufficient blood supply to the brain. There are four types of cerebral ischemia, namely transient ischemic attack (TIA), reversible neurological dysfunction (RIND), progressive stroke (SIE) and complete stroke (CS). TIA does not have cerebral infarction, while RIND, SIE and CS have different degrees of cerebral infarction.
[0003] Amino-6-trifluoromethoxybenzothiazole (riluzole) belongs to the benzothiazole class of compounds. It was initially developed in the 1950s as a central muscle relaxant. In 1995, the US FDA approved riluzole for the treatment of amyotrophic lateral sclerosis (ALS). Riluzole can inhibit the release of glutamate from cultured neurons, brain slices, and in vivo cerebral cortical neurons. These effects may be partly attributed to the inactivation of voltage-dependent sodium channels in glutamatergic nerve terminals and the activation of pertussis toxin (PTX)-sensitive G protein-dependent signal transduction processes; riluzole also inhibits glutamate release from cultured neurons, brain slices, and in vivo cerebral cortical neurons by non-competitively blocking N-methyl-D-aspartate (NMDA) receptors (IC 50 18 µM) and kainic acid receptors (IC 50 167µM) to block certain postsynaptic effects of glutamate. In vivo, riluzole has neuroprotective, anticonvulsant and sedative effects. In a rodent model of transient global cerebral ischemia, riluzole was able to completely inhibit the ischemia-induced surge in glutamate release. In vitro, riluzole protected cultured neurons from hypoxic injury, toxic effects of glutamate uptake inhibitors, and toxic factors in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis ( Neurology, 1996, 47(6 Suppl 4), S233S–41). Subsequently, preclinical animal and clinical human trials found that riluzole has certain therapeutic effects in spinal cord neuroprotection, neuropathic pain, epilepsy, anxiety and depression ( Chinese Journal of Pharmaceutical Sciences Journal of Chemical and Biological Engineering, 2015, 50 (14): 1165-1168; Chemical and Biological Engineering, 2017, 34(2): 6-9 In addition, a systematic review and meta-analysis of riluzole in the treatment of neurodegenerative movement diseases, including PD, atypical Parkinson's disease, Huntington disease (HD), hereditary ataxia, etc., concluded that the effect of riluzole on the symptoms of patients with hereditary ataxia seems promising, but further clinical verification studies are still needed ( Drug Delivery, 2017, 25(1), 43–48 In addition, in the rat middle artery occlusion (MCAO) model, a single intravenous injection of 4 mg / kg and 8 mg / kg riluzole 30 min after ischemia significantly reduced the neurological deficit score and cerebral infarction area in rats (CNS Drug Reviews, 1997, 3(1), 83–101).
[0004] The chemical structure of riluzole is as follows:
[0005]
[0006] Riluzole (molecular formula C8H5F3N2OS; molecular weight 234.20)
[0007] Natural borneol is a kind of borneol from the Lauraceae plant camphor ( Cinnamomum camphora ) fresh branches and leaves are extracted and processed into crystals, the main component of which is (+)-borneol (the 2015 edition of the Chinese Pharmacopoeia stipulates that the content of (+)-borneol in natural borneol should not be less than 96.0%). Blumea balsamifera ) is a crystal extracted from the fresh leaves of the plant. Its main component is (-)-borneol (the 2015 edition of the Chinese Pharmacopoeia stipulates that the content of (-)-borneol in natural borneol should not be less than 85.0%). Synthetic borneol is chemically synthesized, and its main components are (-)-borneol and (-)-borneol. ( Euro J Pharmacol , 2017 811 , 1–11). In addition, under physiological conditions, borneol can also provide drug delivery to the central nervous system by transiently and reversibly increasing the permeability of the blood-brain barrier (BBB); under pathological conditions, it can maintain the integrity of the BBB and protect brain tissue. (Drug Deliv 2017, 24:1037–1044; Drug Deliv 2018, 25:1617–1633; Biomed Pharmacother 2018,102:874–883) In Xenopus oocytes, D-borneol can enhance the expression of recombinant human GABA induced by low concentrations of GABA A R(α1β2γ2L ) function, up to 10 times more, its EC 50 248 µM ( Biochemical Pharmacology, 2005, 69(7), 1101–1111 Natural borneol has a protective effect on glutamate-induced neuronal damage ( Journal of Nanjing Medical University (Natural Science Edition) 2013, 33 (5), 630–635 In addition, dextrorotatory borneol has been used as a raw material in the Class 1 new drug edaravone dextrorotatory borneol injection for the treatment of ischemic stroke (CDE acceptance number CXHS1800031).
[0008] The chemical structure of dextrorotatory borneol is as follows:
[0009]
[0010] Dextrorotatory borneol (molecular formula C 10 H 18 O; molecular weight 154.25). Summary of the invention
[0011] The object of the present invention is to provide a composition for use in preparing a drug for treating cerebrovascular diseases, wherein the drug composition contains 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof and borneol or dextrorotatory borneol. Furthermore, the composition contains 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof and dextrorotatory borneol.
[0012] The above-mentioned pharmaceutical composition is characterized in that the weight ratio of 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof to borneol or dextrorotatory borneol is 30:1 to 1.5:1, preferably 15:1 to 1.5:1, preferably 15:1 to 7.5:1.
[0013] The borneol described in the above composition is natural borneol, L-borneol or synthetic borneol.
[0014] The drug combination of the present invention can be used to prepare cerebrovascular drugs. Among them, the cerebrovascular disease is preferably ischemic cerebrovascular disease, and ischemic stroke is further preferred.
[0015] The beneficial effect of the present invention is that 2-amino-6-trifluoromethoxybenzothiazole and dextrorotatory borneol are compatible, and according to the results of non-clinical cell tests and animal efficacy tests, the two have the effect of synergistically increasing the efficacy of cerebrovascular diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Fig. 1 Effects of riluzole and borneol on NMDA-induced neuronal damage.
[0017] Fig. 2 Inhibition rate of riluzole and dextrorotatory borneol on NMDA-induced neuronal damage.
[0018] Figure 3 Effects of riluzole, dextrorotatory borneol and their combination on NMDA-induced excitability injury in primary neurons.
[0019] Fig. 4 Effects of riluzole, dextrorotatory borneol and their combination (20:1) on NMDA-induced neuronal excitability injury.
[0020] Figure 5 The dose-effect relationship (A), median effect diagram (B), and combination index diagram (C) of the riluzole-dextrorotatory borneol combination (20:1) were calculated using CompuSyn software.
[0021] Fig. 6 Effects of riluzole, dextrorotatory borneol and their combination (5:1) on NMDA-induced neuronal excitability injury.
[0022] Fig. 7 Effects of riluzole, dextrorotatory borneol and their combination (1:1) on NMDA-induced neuronal excitability injury.
[0023] Fig. 8 Effects of riluzole-borneol combination on neurological deficit symptoms in MCAO rats.
[0024] Fig. 9 Effects of the riluzole-borneol combination on cerebral infarction area.
[0025] Figure 10 The dose-effect relationship (A), median effect diagram (B), and combination index diagram (C) of riluzole-dextrorotatory borneol combination (mass ratio 8:1 and 15:1) in reducing cerebral infarction area in MCAO rats were calculated using CompuSyn software.
[0026] Figure 11 Effects of the combination of riluzole with dextrorotatory borneol, borneol and synthetic borneol on the neurological deficit score and cerebral infarction area in MCAO rats. DETAILED DESCRIPTION
[0027] The following examples illustrate the present invention and should not be construed as limiting the present invention.
[0028] Example 1 Effects of riluzole and dextrorotatory borneol on NMDA-induced excitability damage in primary cortical neurons
[0029] 1 Materials and methods
[0030] 1.1 Animals
[0031] SD pregnant rats, Shanghai Slake Experimental Animal Co., Ltd. (Production License No.: SCXK (Shanghai) 2017-0005)
[0032] 1.2 Reagents and consumables
[0033] name Article number / Batch number Manufacturer Neurobasal 21103-049 Gibco B27 17504-044 Gibco GlutaMax 2110349 Gibco CellTiter-Glo G7571 Promega Poly-lysine (PDL) P6407 Sigma DMEM 11995-040 Gibco Sugar-free DMEM 1763966 Gibco Pennicillin Streptomycin (P / S) 15140-122 Gibco Fetal bovine serum (FBS) 10099-141 Gibco Cell Culture Plate Corning 3610 / 96 well cell culture plate Corning Riluzole R129533-5g (Lot1502089) Aladdin Borneol KC20171205-1-2 Jiangsu Ouwei Pharmaceutical Co., Ltd. Luminescent Cell Viability Assay LOT 7E322D9 Nanjing Novozyme Medical Technology Co., Ltd.
[0034] 1.3 Preparation of primary cortical neurons
[0035] SD pregnant rats at 18 days of gestation were killed by cervical dislocation. The rat uterus was dissected to remove the brain of E18 fetuses. The fetal cerebral cortex tissue was separated and placed in ice-cold DMEM. The meninges and blood vessels on the cortical tissue were removed under a dissecting microscope. The cortical tissue was transferred to ice-cold DMEM and cut into pieces (about 1 mm 3 ), digested with trypsin at 37℃ for 10 min, terminated with FBS, gently dispersed with a Pasteur pipette and passed through a 200-mesh sieve. Transfer the filtered cell suspension to a 15 mL centrifuge tube, centrifuged at 1000 rpm for 5 min, discarded the supernatant, and gently dispersed the cell mass at the bottom of the centrifuge tube with complete medium (Neurobasal + B27 + GlutaMax + 1% P / S) preheated at 37℃, counted with a hemocytometer, and diluted to 5×10 with complete medium. 5 Cells / mL were seeded in a 96-well plate coated with PDL for culture (100 μL / well), and the medium was replaced with half of the complete medium every other day. The cells were cultured in vitro until the neurons were differentiated and mature on the 11th day and used for oxygen-glucose deprivation experiments.
[0036] 1.4 NMDA-induced excitability injury test of primary cortical neurons
[0037] The culture medium of in vitro matured primary neurons was replaced with Locke's buffer (NaCl 154mM, KCl 5.6mM, NaHCO3 3.6mM, CaCl2 2.3mM, D-Glucose 5.6mM, HEPES 5mM, pH7.4) containing different concentrations (100, 33.3, 11.1, 3.7, 1.23 and 0.41µM) of riluzole (R) or dextrorotatory borneol. After incubation at 37°C for 10 min, excitability inducers (NMDA final concentration 100 µM and Glycine final concentration 10 µM) were added for induction for 30 min. After aspirating the induction buffer, the cells were washed once with Locke's buffer containing 1mM MgCl2 and replaced with the completion medium (100 μL / well) for a recovery of 4 h.
[0038] 1.5 Neuronal cell viability detection
[0039] Luminescent Cell Viability Assay Kit was used to detect the viability of primary neuronal cells. According to the instructions, 100 μL / well of reagent was added, shaken for 10 min, and the chemiluminescence value (LUM) was read on the SpectraMax i3X (Molecule Device) multi-function plate reader to calculate the relative viability of neurons.
[0040] Calculation formula: Relative neuronal activity V (%) = (LUM-LUM本底 ) / (LUM 正常对照组 -LUM 本底组 )×100%. LUM 本底 For background readings, Luminescent Cell Viability Assay reagent was added to complete medium wells without cells.
[0041] 1.6 Neuroprotective effects of compounds
[0042] The inhibition of neuronal excitatory damage by the compound is used to indicate the neuroprotective effect of the compound on excitatory damage. Relative inhibition rate = 100% × (V 化合物 -V NMDA模型 ) / (V 正常对照组 -V NMDA模型 ), V is the relative activity of neurons.
[0043] Compound EC 50 Fitting: With log[compound concentration] as the horizontal axis and relative inhibition rate as the vertical axis, Prism8 (GraphPad) was used to fit the log(inhibitor) vs. response -- Variable slope (fourparameters) curve and obtain the compound IC 50 .
[0044] 1.7 Statistics
[0045] The experimental data are expressed as mean ± standard deviation (Mean ± SD) (n=3). One-way ANOVA was performed using Prism 8 (GraphPad), and the differences between the two groups were analyzed using Uncorrected Fisher's LSD. P<0.05 was considered significant. ###p<0.001, compared with the control group; *p<0.05, **p<0.01, ***p<0.001, compared with the NMDA model group.
[0046] 2 Experimental Results
[0047] 2.1 Effects of riluzole and borneol on NMDA-induced neuronal injury
[0048] In the concentration range of 0.41-100 μM, riluzole increased NMDA-induced neuronal activity in a concentration-dependent manner, and significantly increased neuronal activity at concentrations of 33.3 and 100 μM ( Figure 1 A); while dextrorotatory borneol increased the activity of excitatory damaged neurons in a concentration-dependent manner at concentrations of 0.41-3.7 μM, but the activity of neurons showed a certain downward trend as the concentration increased (10-100 μM) ( Figure 1 B).
[0049] EC values of riluzole and dextrorotatory borneol for neuroprotection based on compound concentration-inhibition rate curves 50 about 40 μM (E max ~60%) and 2 μM (E max ~15%) Figure 2 ).
[0050] Example 2 Effect of the combination of riluzole and dextrorotatory borneol on NMDA-induced excitability injury in primary cortical neurons
[0051] 1 Materials and methods
[0052] 1.1 Animals Same as in Example 1
[0053] 1.2 Reagents and consumables are the same as in Example 1
[0054] 1.3 Preparation of primary cortical neurons is the same as in Example 1
[0055] 1.4 NMDA-induced excitability injury test of primary cortical neurons
[0056] The culture medium of in vitro matured primary neurons was replaced with Locke's buffer (NaCl 154mM, KCl 5.6mM, NaHCO33.6mM, CaCl2 2.3mM, D-Glucose 5.6mM, HEPES 5mM, pH7.4) containing different concentrations of riluzole (R), dextrorotatory borneol (B) or a combination of riluzole and dextrorotatory borneol (RB) (see Table 1). After incubation at 37°C for 10 min, excitability inducers (NMDA final concentration 100 µM and Glycine final concentration 10 µM) were added for induction for 30 min. After aspirating the induction buffer, the cells were washed once with Locke's buffer containing 1 mM MgCl2 and replaced with the completion medium (100 μL / well) for a recovery of 4 h.
[0057] surface Orthogonal design of the combination of riluzole and dextrorotatory borneol
[0058] DMSO R1 R2 R3 R4 R5 R6 B1 R1 B1 R2B1 R3B1 R4B1 R5B1 R6B1 B2 R1 B2 R2B2 R3B2 R4B2 R5B2 R6B2 B3 R1 B3 R2B3 R3B3 R4B3 R5B3 R6B3 B4 R1 B4 R2B4 R3B4 R4B4 R5B4 R6B4 B5 R1 B5 R2B5 R3B5 R4B5 R5B5 R6B5 B6 R1B6 R2B6 R3B6 R4B6 R5B6 R6B6
[0059] Note: R stands for riluzole, B stands for dextrorotatory borneol, R X B Yrepresents the combination of riluzole and dextrorotatory borneol, and X / Y data 1-6 are the concentrations of the respective compounds, which are 100, 33.3, 11.1, 3.7, 1.23 and 0.41 µM, respectively. Each group of drugs has 5 replicate wells (n=5). All compounds were first dissolved in DMSO, and the final concentration of DMSO in the cell culture medium was 0.2%.
[0060] 1.5 Neuronal cell viability detection Same as Example 1
[0061] 1.6 Data statistics are the same as in Example 1
[0062] The experimental data are expressed as mean ± standard deviation (Mean ± SD) (n=3). One-way ANOVA was performed using Prism 8 (GraphPad), and the differences between the two groups were analyzed using Uncorrected Fisher's LSD. P<0.05 was considered significant. ###p<0.001, compared with the Control group; *p<0.05, **p<0.01, compared with the NMDA model group.
[0063] Experimental Results
[0064] 2.1 Effects of riluzole and borneol combination on excitatory damage of primary neurons
[0065] As shown in 3, within the concentration range of 0.41~100 μM, riluzole alone can significantly inhibit the activity of neurons with NMDA-induced excitotoxic injury at the concentration of R2 (33.3 μM); while dextrorotatory borneol can significantly increase the activity of neurons with NMDA-induced excitotoxic injury only at the concentration of R4 (3.7 μM). The combination of riluzole and dextrorotatory borneol R1B1 (1:1), R2B1 (1:3), R2B2 (1:1), R2B3 (3:1), R2B4 (9:1), R2B5 (27:1), R3B1 (1:9), R3B2 (1:3), R3B3 (1:1), R3B4 (3:1), R3B5 (9:1), R3B6 (1:27), R4B1 (1:27), R4B2 (1:9), R4B3 (1:3), R4B4 (1:1), R4B5 (3:1), R4B6 (9:1) can significantly enhance the neuronal activity induced by NMDA. This indicates that the combination of riluzole and dextrorotatory borneol in a ratio of 27:1 to 1:27 may produce a synergistic effect in neuroprotection.
[0066] Example 3 Study on the synergistic effect of riluzole and dextrorotatory borneol combination (20:1) in protecting primary neurons from excitatory injury
[0067] 1 Materials and methods
[0068] 1.1 Animals Same as in Example 1
[0069] 1.2 Reagents and consumables are the same as in Example 1
[0070] 1.3 Preparation of primary cortical neurons is the same as in Example 1
[0071] 1.4 NMDA-induced excitability injury test of primary cortical neurons
[0072] The culture medium of in vitro matured primary neurons was replaced with Locke's buffer (see Table 2) containing different concentrations of riluzole (R), dextrorotatory borneol (B) or a combination of riluzole and dextrorotatory borneol (20:1). After incubation at 37°C for 10 min, excitability inducers (final concentration of NMDA 100 µM and final concentration of Glycine 10 µM) were added for induction for 30 min. After aspirating the induction buffer, the cells were washed once with Locke's buffer containing 1 mM MgCl2 and replaced with the completion medium (100 μL / well) for a recovery of 4 h.
[0073] Table 2 Riluzole dextrorotatory borneol composition concentration design
[0074] Riluzole(µM) Borneol(µM) 10 / 20 / 40 / 80 / 160 / / 0.5 / 1 / 2 / 4 / 8 10 0.5 20 1 40 2 80 4 160 8
[0075] 1.5 Neuronal cell viability detection Same as Example 1
[0076] 1.6 Neuroprotective effect of the compound is the same as in Example 1
[0077] 1.7 Synergistic analysis of the composition
[0078] CompuSyn software (ComboSyn, Inc) was used to analyze the synergistic effect of the fixed-ratio combination of riluzole and dextrorotatory borneol on the neuroprotective effect.
[0079] 1.8 Statistics
[0080] Experimental data are expressed as mean ± standard deviation (Mean ± SD) (n=3-6). One-way ANOVA was performed using Prism 8 (GraphPad), and the differences between the two groups were analyzed using Uncorrected Fisher's LSD. P<0.05 was considered significant. ###p<0.001, compared with the control group; *p<0.05, **p<0.01, ***p<0.001, compared with the NMDA model group.
[0081] Experimental Results
[0082] 2.1 Effects of riluzole, dextrorotatory borneol, and their combination (20:1) on excitotoxicity in primary neurons
[0083] According to the results of Example 1, the compound concentrations were designed to be 1 / 4 × ED50, 1 / 2 × ED50, 1 × ED50, 2 × ED50 and 4 × ED50, the riluzole concentrations were 10, 20, 40, 80 and 160 μM, the dextrorotatory borneol concentrations were 0.5, 1, 2, 4 and 8 μM, and the molar ratio of the riluzole to dextrorotatory borneol composition was 20:1. Riluzole, dextrorotatory borneol and the combination of the two can increase the activity of NMDA-induced damaged neurons in a concentration-dependent manner, and the combination is superior to riluzole or dextrorotatory borneol ( Figure 4 ).
[0084] 2.2 Analysis of the synergistic effect of riluzole-borneol combination on neuroprotection
[0085] According to the Chou-Talalay equation, the fixed ratio combination index (CI) was calculated using CompuSyn software (see Table 3, Figure 5 ), the CI of the riluzole-dextrorotatory borneol composition (molar ratio of riluzole to dextrorotatory borneol 20:1) was <1, indicating that riluzole and dextrorotatory borneol had a synergistic effect in protecting neurons from excitatory damage.
[0086] Table 3 Effect (Fa) and combination index (CI) of riluzole-dextrorotatory borneol combination on protecting neurons from excitatory injury
[0087]
[0088] Example 4 Study on the synergistic effect of riluzole-deoxy-borneol combination (5:1) in protecting primary neurons from excitatory injury
[0089] 1 Materials and methods
[0090] 1.1 Animals Same as in Example 1
[0091] 1.2 Reagents and consumables are the same as in Example 1
[0092] 1.3 Preparation of primary cortical neurons is the same as in Example 1
[0093] 1.4 NMDA-induced excitability injury test of primary cortical neurons
[0094] The culture medium of in vitro matured primary neurons was replaced with Locke's buffer (see Table 2) containing different concentrations of riluzole (R), dextrorotatory borneol (B) or a combination of riluzole and dextrorotatory borneol (5:1). After incubation at 37°C for 10 min, excitability inducers (final concentration of NMDA 100 µM and final concentration of Glycine 10 µM) were added for induction for 30 min. After aspirating the induction buffer, the cells were washed once with Locke's buffer containing 1 mM MgCl2 and replaced with the completion medium (100 μL / well) for a recovery of 4 h.
[0095] Table 4 Concentration design of riluzole-dexamethasone combination
[0096] Riluzole(µM) Borneol(µM) 2.5 / 5 / 10 / 20 / 40 / / 0.5 / 1 / 2 / 4 / 8 2.5 0.5 5 1 10 2 20 4 40 8
[0097] 1.5 Neuronal cell viability detection Same as Example 1
[0098] 1.6 Neuroprotective effect of the compound is the same as in Example 1
[0099] 1.7 Synergistic analysis of the composition
[0100] CompuSyn software (ComboSyn, Inc) was used to analyze the synergistic effect of the fixed-ratio combination of riluzole and dextrorotatory borneol on the neuroprotective effect.
[0101] 1.8 Data statistics are the same as in Example 3
[0102] 2 Experimental Results
[0103] 2.1 Effects of riluzole, dextrorotatory borneol, and their combination (5:1) on excitotoxicity in primary neurons
[0104] The concentrations of riluzole were 2.5, 5, 10, 20 and 40 μM, the concentrations of dextrorotatory borneol were 0.5, 1, 2, 4 and 8 μM, and the molar ratio of the riluzole-dextrorotatory borneol combination was 5:1. Riluzole, dextrorotatory borneol and the combination of the two can increase the activity of NMDA-induced damaged neurons in a concentration-dependent manner, and the combination (5:1) is superior to riluzole or dextrorotatory borneol ( Figure 6 ).
[0105] 2.2 Analysis of the synergistic effect of riluzole-borneol combination on neuroprotection
[0106] According to the principle of Chou-Talalay equation, CompuSyn software was used to calculate the combination index (CI) of the fixed ratio composition (see Table 5). The CI of the riluzole-dextrorotatory borneol combination (molar ratio of riluzole to dextrorotatory borneol 5:1) was <1, indicating that riluzole and dextrorotatory borneol have a synergistic effect in protecting neurons from excitatory damage.
[0107] Table 5 Effect (Fa) and combination index (CI) of riluzole-dextrorotatory borneol combination on protecting neurons from excitatory injury
[0108]
[0109] Example 5 Study on the synergistic effect of riluzole-deoxyborneol combination (1:1) in protecting primary neurons from excitatory injury
[0110] 1 Materials and methods
[0111] 1.1 Animals Same as in Example 1
[0112] 1.2 Reagents and consumables are the same as in Example 1
[0113] 1.3 Preparation of primary cortical neurons is the same as in Example 1
[0114] 1.4 NMDA-induced excitability injury test of primary cortical neurons
[0115] The culture medium of in vitro matured primary neurons was replaced with Locke's buffer (see Table 2) containing different concentrations of riluzole (R), dextrorotatory borneol (B) or a combination of riluzole and dextrorotatory borneol (1:1). After incubation at 37°C for 10 min, excitability inducers (final concentration of NMDA 100 µM and final concentration of Glycine 10 µM) were added for induction for 30 min. After aspirating the induction buffer, the cells were washed once with Locke's buffer containing 1 mM MgCl2 and replaced with the completion medium (100 μL / well) for a recovery of 4 h.
[0116] Table 6 Concentration design of riluzole-dexamethasone combination
[0117] Riluzole(µM) Borneol(µM) 0.5 / 1 / 2 / 4 / 8 / / 0.5 / 1 / 2 / 4 / 8 0.5 0.5 1 1 2 2 4 4 8 8
[0118] 1.5 Neuronal cell viability detection Same as Example 1
[0119] 1.6 Neuroprotective effect of the compound is the same as in Example 1
[0120] 1.7 Synergistic analysis of the composition
[0121] CompuSyn software (ComboSyn, Inc) was used to analyze the synergistic effect of the fixed-ratio combination of riluzole and dextrorotatory borneol on the neuroprotective effect.
[0122] 1.8 Data statistics are the same as in Example 3
[0123] 2 Experimental Results
[0124] 2.1 Effects of riluzole, dextrorotatory borneol, and their combination (1:1) on excitotoxicity in primary neurons
[0125] The concentrations of riluzole were 0.5, 1, 2, 4 and 8 μM, the concentrations of dextrorotatory borneol were 0.5, 1, 2, 4 and 8 μM, and the molar ratio of riluzole to dextrorotatory borneol was 1:1. The protective effect of riluzole in this concentration range was concentration-dependent to a certain extent, and dextrorotatory borneol and the combination (1:1) could increase the activity of NMDA-induced damaged neurons in a concentration-dependent manner, and the combination (1:1) was superior to riluzole or dextrorotatory borneol ( Figure 7 ).
[0126] 2.2 Analysis of the synergistic effect of riluzole-borneol combination on neuroprotection
[0127] According to the principle of Chou-Talalay equation, CompuSyn software was used to calculate the combination index (CI) of the fixed ratio composition (see Table 7). The CI of the riluzole-dextrorotatory borneol combination (molar ratio of riluzole to dextrorotatory borneol was 1:1) was <1, indicating that riluzole and dextrorotatory borneol had a synergistic effect in protecting neurons from excitatory damage.
[0128] Table 7 Effect (Fa) and combination index (CI) of riluzole-dextrorotatory borneol combination on protecting neuronal excitability injury
[0129]
[0130] Example 6 Study on the protective effect of the combination of riluzole and dextrorotatory borneol on focal cerebral ischemia-reperfusion injury
[0131] 1 Materials and methods
[0132] 1.1 Experimental animals
[0133] Sprague-Dawley (SD) rats, male, SPF grade, weighing 250-280 g.
[0134] 1.2 Test Drugs
[0135] Riluzole and dextrorotatory borneol are the same as those in Example 1.
[0136] 1.3 Experimental methods
[0137] 1.3.1 Preparation of focal cerebral ischemia-reperfusion model
[0138] The rat focal cerebral ischemia-reperfusion model was prepared by internal carotid artery embolization. The rats were anesthetized and their limbs (the hind limbs were fixed above the knee joints, and the forelimbs were fixed above the wrist joints) and heads were tied with rubber bands. The animals were fixed on the operating table in a supine position. The hair was shaved from the head to the chest with an animal shaver, and the skin was disinfected with alcohol. The neck was incised in the middle and the subcutaneous tissue was bluntly separated. The thin layer of fascia on the surface of the anterior cervical triangle was separated, and the lower edge of the lower side-claviohyoid muscle was lifted. The longitudinal pulsating artery parallel to this muscle was visible. The arterial shell was opened to expose the right carotid bifurcation. The right common carotid artery, external carotid artery, and internal carotid artery were separated. The vagus nerve was gently peeled off, and the external carotid artery was ligated and cut. The proximal end of the common carotid artery was clamped, and an incision was made from the distal end of the ligature of the external carotid artery. The embolization line was inserted through the common carotid bifurcation into the internal carotid artery, and then slowly inserted until there was slight resistance (about 20 mm from the bifurcation), blocking all blood supply to the middle cerebral artery. The suture was fixed slightly below the incision of the external carotid artery with silk thread, the silk thread clamped at the proximal end of the common carotid artery was loosened, the wound was covered with gauze soaked in sterile saline, and the rat was placed on a warming pad for warmth. After 2.0 h of right cerebral ischemia, the suture was gently pulled out, blood supply was restored for reperfusion, the external carotid artery was ligated with the silk thread that fixed the suture, the skin was sutured, and disinfected. The rat was placed in clean feed, and the general condition and breathing were observed until the rat woke up from anesthesia; food and water were added, and the rat was fed normally.
[0139] 1.3.2 Animal grouping and drug administration
[0140] The experimental animals were divided into 9 groups: riluzole group (6 mg / kg and 12 mg / kg, iv), dextrorotatory borneol group (0.4 mg / kg and 0.8 mg / kg, iv), riluzole dextrorotatory borneol combination group (6.4 mg / kg and 12.8 mg / kg, iv, riluzole: dextrorotatory borneol = 15:1) and model group. After the cerebral ischemia model was prepared, the animals were equally and blindly assigned to each group. The animals were intravenously administered once immediately after reperfusion, and the animals in the model group were given an equal volume of normal saline. Neurological deficits were evaluated 24 hours after cerebral ischemia, and then the animals were killed, the brains were removed, stained, and photographed to determine the area of cerebral infarction.
[0141] 1.3.3 Neurological deficit symptom score and determination of cerebral infarction area
[0142] The modified Bederson 5-point system was used to evaluate neurological deficit symptoms. The single-blind method was used to evaluate the neurological deficit symptoms of rats after cerebral ischemia, that is, the experimental designer marked the animals by group, and the experimenter who scored the neurological deficit symptoms did not know the grouping of the animals. After the scoring, the scorer submitted the scoring results of various marks to the designer, who unblinded and obtained the score of each animal in each experimental group.
[0143] Appendix: Neurological deficit symptom scoring Bederson 5-point system
[0144] 0 When the animal is suspended by its tail, both of its forelimbs are extended toward the floor, and there are no other behavioral defects.
[0145] 1 When the tail is lifted and suspended in the air, the animal's surgical contralateral (left) forelimb shows wrist and elbow flexion, shoulder internal rotation, elbow abduction, and close to the chest wall.
[0146] 2 Place the animal on a smooth flat surface and push the operated shoulder toward the opposite side until the resistance decreases.
[0147] 3 When the animal is walking freely, it will circle or turn toward the side opposite to the surgery.
[0148] 4 Limb paralysis, no spontaneous movement
[0149] The TTC staining method was used to determine the degree of cerebral infarction. After the evaluation of the neurological deficit symptoms of the animals, they were killed with CO2, the brains were removed by decapitation, the olfactory bulbs, cerebellum and lower brain stem were removed, the blood on the surface of the brain was rinsed with saline, the residual water on the surface was sucked off, and it was placed at -20℃ for 20 min. After being taken out, a coronal section was made vertically downward at the cross-line of vision plane, and a slice was cut every 2 mm backward. The brain slices were placed in 1% TTC dye solution and incubated (37℃ 30min). Normal brain tissue was stained dark red, and ischemic brain tissue was pale. After being rinsed with saline, the brain slices were quickly arranged in a row from front to back, the residual water on the surface was sucked off, and photos were taken.
[0150] Calculation of cerebral infarction area: The photos were processed with Image J software, and the corresponding area of the left brain and the non-infarct area of the right brain were calculated according to the formula to obtain the percentage of infarction range.
[0151] Infarct volume calculation method:
[0152] V=t (A1+ A2+ A3+ ………+An)
[0153] t is the slice thickness, and A is the infarct area.
[0154] %I=100%×(V C -V L ) / V C
[0155] %I is the percentage of infarct volume, V C is the brain volume of the control side (left hemisphere), V L is the volume of the non-infarcted area on the infarcted side (right cerebral hemisphere).
[0156] 1.4 Synergistic analysis of the composition
[0157] CompuSyn software (ComboSyn, Inc) was used to analyze the neuroprotective effect of the non-fixed ratio combination of riluzole and dextrorotatory borneol.
[0158] 1.5 Statistics
[0159] Experimental data are expressed as mean ± standard deviation (Mean ± SD) (n = 10). One-way ANOVA followed by Fisher's LSD was used to analyze the differences between the two groups. P < 0.05 indicated a significant difference. *p < 0.05, **p < 0.01, ***p < 0.001, compared with the MCAO model; ns indicates no statistical difference between the groups shown in the figure.
[0160] 2 Experimental Results
[0161] 2.1 Effects of riluzole-borneol combination on neurological deficit symptoms
[0162] like Figure 8 As shown, riluzole, dextrorotatory borneol and the combination can reduce the neurological deficit scores of MCAO rats in a dose-dependent manner. Compared with the MCAO model group, the neurological deficit scores of MCAO rats in the riluzole 8 mg / kg group, dextrorotatory borneol 1 mg / kg group, combination (riluzole to dextrorotatory borneol mass ratio 8:1) 4.5 mg / kg and 9 mg / kg groups, and combination (riluzole to dextrorotatory borneol mass ratio 15:1) 6.4 mg / kg and 12.8 mg / kg groups were significantly reduced. In addition, compared with the riluzole or dextrorotatory borneol groups, the neurological deficit scores of the combination group tended to be lower.
[0163] 2.2 Effect of riluzole-borneol combination on cerebral infarction area
[0164] like Figure 8 As shown, compared with the MCAO model group, the 4 and 8 mg / kg riluzole groups, the 0.5 and 1 mg / kg dextrorotatory alcohol groups, the combination (the mass ratio of riluzole to dextrorotatory alcohol is 8:1) 4.5 mg / kg and 9 mg / kg (8:1), and the combination (the mass ratio of riluzole to dextrorotatory alcohol is 15:1) 6.4 mg / kg and 12.8 mg / kg dose-dependently and significantly reduced the cerebral infarction area. In addition, compared with the riluzole or dextrorotatory alcohol groups, the animals in the combination group had a lower cerebral infarction area.
[0165] 2.3 Analysis of the synergistic effect of riluzole-dextrorotatory borneol combination in reducing cerebral infarction area
[0166] According to the Chou-Talalay equation, the combination index (CI) of non-fixed ratio compositions was calculated using CompuSyn software (see Table 8, Fig.10), the CI of the riluzole-dextrorotatory borneol composition (the mass ratio of riluzole to dextrorotatory borneol was 8:1) was <1, indicating that riluzole and dextrorotatory borneol had a synergistic effect in reducing the cerebral infarction area of MCAO rats.
[0167] Table 8 Effect (Fa) and combination index (CI) of riluzole-dextrorotatory borneol combination on reducing cerebral infarction area in MCAO
[0168]
[0169] Example 7 Study on the protective effect of the combination of riluzole, dextrorotatory borneol, levorotatory borneol and synthetic borneol on focal cerebral ischemia-reperfusion injury
[0170] 1 Materials and methods
[0171] 1.1 Experimental animals are the same as in Example 6
[0172] 1.2 Test drug
[0173] Riluzole and dextrorotatory borneol are the same as those in Example 1.
[0174] L-Borneol and synthetic borneol were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0175] 1.3 Experimental methods
[0176] 1.3.1 Preparation of focal cerebral ischemia-reperfusion model is the same as in Example 6
[0177] 1.3.2 Animal grouping and drug administration
[0178] The experimental animals were divided into 4 groups: riluzole group, dextrorotatory borneol combination group (8 mg / kg riluzole and 1 mg / kg dextrorotatory borneol, iv), riluzole-L-borneol combination group (8 mg / kg riluzole and 1 mg / kg L-borneol), riluzole-synthetic borneol combination group (8 mg / kg riluzole and 1 mg / kg synthetic borneol) and model group. After the cerebral ischemia model was prepared, the animals were equally and blindly assigned to each group. The animals were intravenously administered once immediately after reperfusion, and the animals in the model group were given an equal volume of normal saline. Neurological deficits were evaluated 24 hours after cerebral ischemia, and then the animals were killed, the brains were removed, stained, and photographed to determine the area of cerebral infarction.
[0179] 1.3.3 Determination of neurological deficit symptom score and cerebral infarction area is the same as in Example 6
[0180] 1.4 Statistics
[0181] Experimental data are expressed as mean ± standard deviation (Mean ± SD) (n = 10). One-way ANOVA followed by Fisher's LSD was used to analyze the differences between the two groups. P < 0.05 indicated a significant difference. *p < 0.05, **p < 0.01, ***p < 0.001, compared with the MCAO model; ns indicates no statistical difference between the groups shown in the figure.
[0182] Experimental Results
[0183] 2.1 Effects of the composition on neurological deficit symptoms and cerebral infarction area in MCAO rats
[0184] like Fig.11 As shown in the results, the combination of riluzole (8 mg / kg) and dextrorotatory borneol (1 mg / kg), levorotatory borneol (1 mg / kg) or synthetic borneol (1 mg / kg) can significantly reduce the neurological deficit score and cerebral infarction area in MCAO rats. In addition, there is no difference between the three compositions in neurological deficit score and cerebral infarction area.
Claims
1. Use of a composition in the preparation of a neuroprotective drug, the composition consisting of 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof and dextrorotatory borneol; The weight ratio of the 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof to dextrorotatory borneol is 15:1-1.5:
1.
2. A composition for use in the preparation of a drug for treating cerebrovascular disease, the composition comprising 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof and synthetic borneol in a weight ratio of 8:1; Or it is composed of the 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof and dextrorotatory borneol in a weight ratio of 8:1; Or it is composed of the 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof and L-borneol in a weight ratio of 8:1; The cerebrovascular disease is ischemic cerebrovascular disease.
3. The use according to claim 1, characterized in that The weight ratio of the 2-amino-6-trifluoromethoxybenzothiazole or a pharmaceutically acceptable salt thereof to dextrorotatory borneol is 15:1-7.5:1.
Citation Information
Patent Citations
Pharmaceutical composition and application thereof to preparation of medicament for treating cerebrovascular disease
CN102485223A
Pharmaceutical composition and application of same in preparation of medicines used for treating cerebrovascular diseases
CN103070861A
A pharmaceutical composition comprising butylphthalide and borneol and applications thereof
CN104224772A
Pharmaceutical composition and application thereof
CN105267222A
Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis
CN107613976A
